UAE at a glance
- Population
- 11.5 million 2025
- Life expectancy at birth
- 83.1 years, 2024
- People aged 65 and over
- 1.8 % of people, 2025
- Health spending per person
- 2,402 US$ per person, 2023
- Doctors
- 2.99 per 1,000 people, 2023
Updated
Reviewed by Chandani Patel
UAE Apheresis Equipment Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Product Type, By Procedure, By Technology, By Application, By End User, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$12.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $13.6 Mn | — | — |
| 2025 (base) | $14.6 Mn | +$1.0 Mn | — |
| 2026 (forecast) | $15.6 Mn | +$1.1 Mn | +7.2% |
| 2027 (forecast) | $16.8 Mn | +$1.1 Mn | +14.9% |
| 2028 (forecast) | $18.0 Mn | +$1.2 Mn | +23.2% |
| 2029 (forecast) | $19.3 Mn | +$1.3 Mn | +32.1% |
| 2030 (forecast) | $20.7 Mn | +$1.4 Mn | +41.6% |
| 2031 (forecast) | $22.1 Mn | +$1.5 Mn | +51.8% |
| 2032 (forecast) | $23.7 Mn | +$1.6 Mn | +62.7% |
| 2033 (forecast) | $25.5 Mn | +$1.7 Mn | +74.4% |
| 2034 (forecast) | $27.3 Mn | +$1.8 Mn | +87% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $14.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $27.3 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product type, procedure, technology, application and end user (see all) |
| Key players | Fresenius Kabi AG, Terumo Corporation, B. Braun Melsungen AG, Haemonetics Corporation, Asahi Kasei Medical Co., Ltd. and 1 more (see all) |
| Regulator in the UAE | EDESource: Emirates Drug Establishment. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Apheresis is a procedure that enables healthcare providers to obtain or remove red blood cells, white blood cells, platelets and plasma for medical treatment. It’s also known as pheresis or hemapheresis. In apheresis, a centrifuge machine draws blood from your body and spins the blood to separate its elements. The machine sets aside certain elements and returns the remaining blood cells, platelets and plasma to your body.
The apheresis equipment market is expanding due to rising chronic diseases, technological advancements, and growing awareness of blood donation. Key drivers include the increasing need for blood components and improvements in apheresis technology. However, high costs and regulatory challenges may hinder growth. The market is segmented by product type, application, and end-user, with North America and Europe leading, while Asia-Pacific is expected to experience significant growth. Major players in the market include Terumo BCT, Fresenius Kabi, and Haemonetics Corporation. Overall, the market is set for growth with continued technological innovations and increased healthcare investments.
As chronic diseases continue rising, so does the need for apheresis- a treatment that separates and eliminates specific unhealthy components in the bloodstream. There has been significant progress in technology regarding apheresis equipment, making the instruments safe and efficient. The demand for blood components has also risen as there is a growing awareness of blood disorders in developed regions, and the availability of favourable reimbursement policies. Furthermore, the development of healthcare facilities in the growth horns such as emerging markets also aid in increasing the usage of apheresis equipment.
Further development of apheresis equipment includes, new applications in regenerative medicine and gene therapies, looking at AI, ML, and IoT for improving apheresis equipment, cost-effective and portable machines to make them more accessible. Alliances and partnerships are also known to influence innovation and market advancement.
High initial cost of capital which is likely to lead to low uptake and create budget constrains especially among the developing countries. Tough regulatory standards are often a hindrance to the fast approval of products and the integration of new technologies into the market. One of the challenges that can impede market adoption is a lack of qualified personnel able to operate apheresis equipment.
September 2025, Sanguine Biosciences (Sanguine), a leader in connecting patients with biomedical researchers to accelerate precision medicine R&D, this week announced its opening of a blood donor centre in Los Angeles. The centre will specialize in collecting concentrated white blood cell biospecimens through apheresis from participants in Sanguine’s Patient Community network.
June 2022, NHS England Chooses Spectra Optia® Apheresis System as Part of MedTech Funding Mandate for Expansion of Sickle Cell Disease Treatment. Adoption of Terumo Blood and Cell Technologies’ Spectra Optia will Save the UK’s NHS an Expected GBP 13 Million per Year.
The Emirates Drug Establishment (EDE), set up in 2023, is taking over the regulation of medical devices from the Ministry of Health and Prevention.[1] Since January 2025, basic health insurance has been mandatory for all private-sector employees and domestic workers in every emirate.[2]
[1] Emirates Drug Establishment. Checked 14 Nov 2026.
[2] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Policies within the healthcare sector focusing on better technologies in medicine, as well as the management of chronic diseases, will exercise positive influence on apheresis equipment adoption. Less restrictive FDA regulations and increased emphasis on chronic diseases can drive market expansion. Hypothenar access, especially in areas such as North America, increases the utilization of apheresis procedures; however, inconsistencies in reimbursement practices around the world may affect adoption. Emerging markets have potential for better reimbursement conditions and availability of apheresis treatments when healthcare systems and related infrastructure evolve.
What doctors and scientists are doing in Apheresis Equipment right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.
From our blog
UAE · 1 shared keyword
UAE
UAE
UAE
UAE
UAE
Pharmaceuticals · UAE
Pharmaceuticals · UAE
Pharmaceuticals · UAE
Pharmaceuticals · UAE
Pharmaceuticals · UAE
Healthcare Services · UAE